Get started
Author

Oezlem Tureci

Definition of tumor-associated antigens in hepatocellular carcinoma.
2000 · F Stenner-Liewen, G Luo, et al. · PubMed · 50
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.
2016 · Salah-Eddin Al-Batran, Martin H. Schuler, et al. · Journal of Clinical Oncology · 47
Expression of cancer/testis antigens in cutaneous T cell lymphomas
2001 · Andreas C. Häffner, Anatoli Tassis, et al. · International Journal of Cancer · 32
PDF
A shared tumor-antigen RNA-lipoplex vaccine with/without anti-PD1 in patients with checkpoint-inhibition experienced melanoma.
2020 · Carmen Loquai, Jessica Cecile Hassel, et al. · Journal of Clinical Oncology · 23
IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial.
2015 · Ugur Sahin, Salah-Eddin Al-Batran, et al. · Journal of Clinical Oncology · 22
First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.
2015 · Ugur Sahin, Dirk Jaeger, et al. · Journal of Clinical Oncology · 20
Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.
2013 · Martin H. Schuler, Zanete Zvirbule, et al. · Journal of Clinical Oncology · 18
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.
2016 · Salah-Eddin Al-Batran, Martin H. Schuler, et al. · Journal of Clinical Oncology · 16
A first-in-human dose escalation and dose-finding phase I/II trial of IMAB027 in patients with recurrent advanced ovarian cancer (GM-IMAB-002-01).
2014 · Dirk Jaeger, Ugur Sahin, et al. · Journal of Clinical Oncology · 6
Expression of cancer/testis antigens in cutaneous T cell lymphomas
2002 · Andreas C. Häffner, Anatoli Tassis, et al. · International Journal of Cancer · 1
Works count: 10
Citation count: 235
H-index: 8
I10-index: 8
Year
Topic
Type